Clinical Trials
29 trialsRituximab for PTLD Prevention in Solid Organ Transplant Recipients With EBV DNAemia
Columbia University
Viral Specific T-Lymphocytes to Treat Adenovirus, CMV and EBV
Stanford University
Individualized Treatment Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
NRG Oncology
Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma
University of California, San Francisco
Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT
Chinese PLA General Hospital
Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation
Chinese PLA General Hospital
IDEP
University Hospital, Basel, Switzerland
RACSMEI
Institut Pasteur du Cambodge
Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study
National Taiwan University Hospital
VSTs
Children's Hospital Medical Center, Cincinnati
Third Party Viral Specific T-cells (VSTs)
Children's Hospital Medical Center, Cincinnati
CILESTE
Baylor College of Medicine
Zuberitamab for EBV Infection Post-Allo-HSCT
Institute of Hematology & Blood Diseases Hospital, China
RIS - EBVD
Centre Hospitalier Universitaire de Nīmes
EVITA
University of Aarhus
Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies
Stanford University
A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)
Thomas Jefferson University
Comparative Autoantibody and Immunologic Cell Marker Study
Emory University
EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases.
The Affiliated Hospital of Xuzhou Medical University
A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA
National Health Research Institutes, Taiwan
Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
Stanford University
EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection
New York Medical College
TETRAVI
Baylor College of Medicine
TETRAVI Expanded Access Program
Baylor College of Medicine
R-MVST Cells for Treatment of Viral Infections in Children and Young Adults
Columbia University
TRACE
University Hospital Freiburg
DOTTI
Baylor College of Medicine
Gamma Capture
University of Pittsburgh